The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/36076
StudyName: Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
Date of export from the portal: 02.07.2020
Copyright Holder: See clinicaltrials.gov
Date of Upload / last change: 14.04.2019
License: Creative Commons BY 4.0

----

Description: 
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT02422199
